FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1546857433> ?p ?o ?g. }

• W1546857433 endingPage "324" @default.
• W1546857433 startingPage "324" @default.
• W1546857433 abstract "To the Editor: The dangers of epidemiologic associations are worthy of consideration. It is common to see correlations between the use of β-agonist aerosols and the apparent worsening of asthma. However, the alternative agents—including steroid aerosols and cromolyn sodium—could also be shown to have similar patterns of increased use. In the United Kingdom, there is no increase in death rate, and in most other countries where β2-agonists are favored, there are no clearly established (or even presumed) correlations with their use and subsequent worsening of asthma, other obstructive diseases, or death. Canada and New Zealand seem to be the countries with major anomalies. In the United States, the death rate from asthma remains low, and the risk groups for inadvertent outcomes are poorly educated or disadvantaged patients. An appropriate analogy is, not cigarette smoking, but tuberculosis (TB): the increased problems of TB currently relate to poor access to care, to poverty, and to noncompliance with effective therapy. The analogy with TB may be taken further. Just as isoniazid alone suffices in minor infection, so can β2-agonist aerosols suffice in asthma. And more severe, active disease in each situation necessitates combination therapy. There may be isoniazid-resistant disease, and there may be β-agonist resistant bronchospasm. Both used to be recognized and managed appropriately when they occurred. The fault lies not with the drugs, but in the management of the disease. Furthermore, to put the cigarette analogy to rest, asthmatic patients using only a β agonist do not appear to develop subtle deterioration; therefore, most younger patients “grow out” of asthma and most older patients die after long, comfortably managed lives with asthma or COPD rather than prematurely because of uncontrolled disease or because of the treatment. Although Dr. Cockcroft believes in treating resting bronchoconstriction with steroids, it is all too clear that this never “cures” the disease, and often it leads to years of corticosteroid-based management. Such patients do get asthma exacerbations, and then they immediately require oral steroids. The danger of anti-inflammatory-based therapy is that the patients are admitted into the overall steroid approach to care and they may be more likely to eventually suffer from steroid complications, which can be just as bad or worse than β-agonist difficulties. Thus, choose your aerosol! None of them cure asthma, yet none of them as drugs seem to be unacceptably harmful. Patient education and appropriate drug combinations for more severe disease seem to be equally successful in the vast majority of asthmatics. I am sure that experienced physicians will not change their belief that β-agonists always have been excellent basic therapy for their patients with asthma, bronchitis, and COPD. We must avoid frightening physicians and patients away from these valuable and generally safe bronchodilators. β-Agonists and Bronchial AsthmaCHESTVol. 106Issue 1PreviewTo the Editor: Full-Text PDF" @default.
• W1546857433 created "2016-06-24" @default.
• W1546857433 creator A5069645953 @default.
• W1546857433 date "1994-07-01" @default.
• W1546857433 modified "2023-09-25" @default.
• W1546857433 title "β-Agonists and Bronchial Asthma" @default.
• W1546857433 cites W1807445710 @default.
• W1546857433 cites W1810228914 @default.
• W1546857433 cites W1976390089 @default.
• W1546857433 cites W1976628725 @default.
• W1546857433 cites W2050904082 @default.
• W1546857433 cites W2076992862 @default.
• W1546857433 cites W2104154820 @default.
• W1546857433 cites W2527256827 @default.
• W1546857433 doi "https://doi.org/10.1016/s0012-3692(16)39024-9" @default.
• W1546857433 hasPublicationYear "1994" @default.
• W1546857433 type Work @default.
• W1546857433 sameAs 1546857433 @default.
• W1546857433 citedByCount "1" @default.
• W1546857433 crossrefType "journal-article" @default.
• W1546857433 hasAuthorship W1546857433A5069645953 @default.
• W1546857433 hasConcept C126322002 @default.
• W1546857433 hasConcept C142724271 @default.
• W1546857433 hasConcept C170493617 @default.
• W1546857433 hasConcept C177713679 @default.
• W1546857433 hasConcept C179755657 @default.
• W1546857433 hasConcept C187212893 @default.
• W1546857433 hasConcept C203014093 @default.
• W1546857433 hasConcept C2776042228 @default.
• W1546857433 hasConcept C2776967927 @default.
• W1546857433 hasConcept C2778088044 @default.
• W1546857433 hasConcept C2778938600 @default.
• W1546857433 hasConcept C2779134260 @default.
• W1546857433 hasConcept C2781069245 @default.
• W1546857433 hasConcept C71924100 @default.
• W1546857433 hasConceptScore W1546857433C126322002 @default.
• W1546857433 hasConceptScore W1546857433C142724271 @default.
• W1546857433 hasConceptScore W1546857433C170493617 @default.
• W1546857433 hasConceptScore W1546857433C177713679 @default.
• W1546857433 hasConceptScore W1546857433C179755657 @default.
• W1546857433 hasConceptScore W1546857433C187212893 @default.
• W1546857433 hasConceptScore W1546857433C203014093 @default.
• W1546857433 hasConceptScore W1546857433C2776042228 @default.
• W1546857433 hasConceptScore W1546857433C2776967927 @default.
• W1546857433 hasConceptScore W1546857433C2778088044 @default.
• W1546857433 hasConceptScore W1546857433C2778938600 @default.
• W1546857433 hasConceptScore W1546857433C2779134260 @default.
• W1546857433 hasConceptScore W1546857433C2781069245 @default.
• W1546857433 hasConceptScore W1546857433C71924100 @default.
• W1546857433 hasIssue "1" @default.
• W1546857433 hasLocation W15468574331 @default.
• W1546857433 hasOpenAccess W1546857433 @default.
• W1546857433 hasPrimaryLocation W15468574331 @default.
• W1546857433 hasRelatedWork W2029812690 @default.
• W1546857433 hasRelatedWork W2078978147 @default.
• W1546857433 hasRelatedWork W2085858723 @default.
• W1546857433 hasRelatedWork W2278869839 @default.
• W1546857433 hasRelatedWork W2938256657 @default.
• W1546857433 hasRelatedWork W3162143235 @default.
• W1546857433 hasRelatedWork W4210941341 @default.
• W1546857433 hasRelatedWork W4213108589 @default.
• W1546857433 hasRelatedWork W927468184 @default.
• W1546857433 hasRelatedWork W2549899986 @default.
• W1546857433 hasVolume "106" @default.
• W1546857433 isParatext "false" @default.
• W1546857433 isRetracted "false" @default.
• W1546857433 magId "1546857433" @default.
• W1546857433 workType "article" @default.